Day Traders Tag icon

×
Tuesday, Valneva SE (NASDAQ:VALN) and Pfizer Inc. (NYSE:PFE) released immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose. One month after receiving the second booster dose, the immune response and safety profile of VLA15 were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination before each Lyme season. Also Read: Pfizer/Valneva’s Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026. A high proportion of participants seroconverted after the second booster dose, yielding seroconversion rates (SCRs) above 90% for ...


In The news